에서 실시간으로 운영 중이에요! 자세히 알아보기

Abbott

ABT

시가총액 US$1815억

104.89 USD

+0.21

0.2%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

104.13

-0.76

0.72%

1일

0.2%

5일

4.89%

1개월

2.47%

3개월

6.13%

6개월

9.87%

연초 이후

-15.54%

1년

-17.82%

5년

-10.21%

10년

158.41%

소개: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

직원 수: 115,000

건강관리 의료기기

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 50.5%

중립 45.4%

부정적 4.1%

Zacks Investment Research

Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.

Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

24/7 Wall Street

3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades

Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics.

3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades

Longleaf Partners Global Fund Q3 2026 Portfolio Review

Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. In the first part of the year before we invested, Abbott slightly missed earnings estimates while it was digesting its acquisition of Exact Sciences, along with a variety of turmoil in the medtech and infant nutrition industries. Digital and print publisher People Inc. was a detractor in the quarter, while hospitality and entertainment company MGM Resorts also detracted.

Longleaf Partners Global Fund Q3 2026 Portfolio Review

24/7 Wall Street

Medtronic Pays More Today. Abbott Raises Its Dividend Faster.

Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than you expect.

Medtronic Pays More Today. Abbott Raises Its Dividend Faster.

Longleaf Partners Fund Q3 2026 Portfolio Review

The market is regaining confidence in Avantor's ability to grow organically and in Emmanuel Ligner's turnaround plan. Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. Building products company Fortune Brands Innovations saw its stock price decline in Q3, retracing Q2's positive move related to excitement over Jesse Singh's appointment as CEO.

Longleaf Partners Fund Q3 2026 Portfolio Review

The Motley Fool

The Market Is Flashing Warning Signals Not Seen in Years. Here's Why I Just Bought 3 of SCHD's Dividend Kings.

The Shiller CAPE ratio hasn't been this high since the dot-com era. I'm building more defensive ballast in my portfolio by investing in Dividend Kings.

The Market Is Flashing Warning Signals Not Seen in Years. Here's Why I Just Bought 3 of SCHD's Dividend Kings.

Zacks Investment Research

Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings?

ABT's Q3 earnings are likely to have benefited from Diagnostics growth, Medical Device momentum and Nutrition innovations, while its valuation below historical levels draw investor interest.

Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings?

Zacks Investment Research

Abbott (ABT) Gains As Market Dips: What You Should Know

Abbott (ABT) closed the most recent trading day at $101.82, moving +2.23% from the previous trading session.

Abbott (ABT) Gains As Market Dips: What You Should Know

The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories provides stability through a massive, diversified portfolio of diagnostics, nutrition, and medical devices. Intuitive Surgical dominates the robotic-assisted surgery market with high growth and exceptional cash reserves.

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

History Says Abbott Stock Could More Than Double by 2036. Here's Why I Just Added It to My Portfolio.

Abbott has grown its earnings per share at a nearly 10% compound annual rate over the past decade. Its stock price could more than double by 2036 using a more conservative 8% growth rate.

History Says Abbott Stock Could More Than Double by 2036. Here's Why I Just Added It to My Portfolio.

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.